medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

Title: Performance characteristics of the VIDAS® SARS-COV-2 IgM and IgG serological assays

Running title: VIDAS® SARS-COV-2 IgM and IgG assay performance

Nathalie Renard[a#], Soizic Daniel[a], Nadège Cayet[a], Matthieu Pecquet[b], Frédérique Raymond[a], Sylvie Pons[c], Julien Lupo[d], Carole Tourneur[a], Catherine Pretis[a], Guillaume Gerez[a], Patrick Blasco[a], Maxime Combe[a], Imen Canova[a], Mylène Lesénéchal[a#], Franck Berthier[a]

[a]R&D bioMérieux, 376 Chemin de l'orme, 69280 Marcy l'Etoile, FRANCE

[b]Laboratoire de Biologie, Centre Hospitalier Saint Joseph Saint Luc, 20 Quai Claude Bernard, 69007 Lyon, FRANCE

[c]Laboratoire commun de recherche Hospices Civils de Lyon - bioMérieux, Centre Hospitalier Lyon-Sud, Bâtiment 3F, Chemin du Grand Revoyet, 69310 Pierre-Bénite, FRANCE

[d]Institut de Biologie Structurale (IBS), CEA, CNRS, Université Grenoble-Alpes; Laboratoire de Virologie, Centre hospitalier Universitaire Grenoble-Alpes, CS10217, 38043 Grenoble cedex 09, FRANCE

[#]Nathalie Renard : Nathalie.RENARD@biomerieux.com

[#]Mylène Lesénéchal : mylene.lesenechal@biomerieux.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

ABSTRACT

The COVID-19 pandemic, caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread worldwide. Serological testing for SARS-CoV-2-specific antibodies plays an important role in understanding and controlling the pandemics, notably through epidemiological surveillance. Well validated and highly specific SARS-CoV-2 serological assays are urgently needed. We describe here the analytical and clinical performance of VIDAS® SARS-CoV-2 IgM and VIDAS® SARS-CoV-2 IgG, two CE-marked, EUA-authorized, automated, qualitative assays for the detection of SARS-CoV-2-specific IgM and IgG, respectively. Both assays showed high within-run and within-laboratory precision (coefficients of variation < 11.0%) and very low cross-reactivity towards sera of patients with a past common coronavirus or respiratory virus infection. Clinical specificity determined on up to 989 pre-pandemic healthy donors was ≥ 99% with a narrow 95% confidence interval for both IgM and IgG assays. Clinical sensitivity was determined on up to 232 samples from 130 RT-PCR-confirmed SARS-CoV-2 patients. The positive percent agreement (PPA) with SARS-CoV-2 PCR reached 100% at ≥ 16 days (VIDAS® SARS-CoV-2 IgM) and ≥ 32 days (VIDAS® SARS-CoV-2 IgG) of symptom onset. Combined IgM/IgG test results improved the PPA compared to each test alone. SARS-CoV-2 IgG seroconversion followed closely that of SARS-CoV-2 IgM and remained stable over time, while SARS-CoV-2 IgM levels rapidly declined. Interestingly, SARS-CoV-2-specific IgM and IgG responses were significantly higher in COVID-19 hospitalized vs. non-hospitalized patients. Altogether, the VIDAS® SARS-CoV-2 IgM and IgG assays are highly specific and sensitive serological tests suitable for the reliable monitoring of past SARS-CoV-2 infections and for seroepidemiology investigations.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

INTRODUCTION

Coronavirus disease 19 (COVID-19) is an infectious disease caused by the newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1, 2). Within three months of its emergence in China in December 2019, COVID-19 has been declared a global pandemic by the World Health Organisation (WHO). As of September 25, 2020, nearly 32 million COVID-19 cases and 980,000 deaths have been reported worldwide (3–5). Accurate diagnosis is essential in managing the pandemic, not only to identify, isolate and treat affected patients, but also to characterize the epidemiology of virus transmission and develop national and international surveillance programs. WHO recommends molecular testing of SARS-CoV-2 nucleic acids for acute-phase diagnosis of suspected cases (6–8). Several nucleic acid amplification tests (NAATs), mostly based on quantitative reverse transcriptase polymerase chain reaction (RT-qPCR), have received the Conformité Européenne (CE) mark and have been approved by the United States Food and Drug Administration (FDA) under emergency use authorization (EUA) (9–11). On the other hand, serological testing for SARS-CoV-2-specific antibodies, especially immunoglobulin M (IgM) and immunoglobulin G (IgG), is not recommended for the diagnosis of acute cases. It plays however an essential role in the diagnosis of past SARS-CoV-2 infection and in ongoing immunological and epidemiological surveillance. Serological testing might also complement molecular testing to confirm suspected cases not detected by molecular assays, either due to late (> 7 days after infection) or improper sample collection. Finally, serology screening may allow the identification of convalescent plasma donors for use as potential therapy against COVID-19 (9–21).

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

SARS-CoV-2 serological testing is facing several challenges. Among them, sensitivity and specificity should be well defined for the target population and validated at different post-infection time windows. Specificity is particularly critical in the current pandemic phase, as seroprevalence in the population is still low. In such low-incidence settings, a specificity > 99% and a narrow 95% confidence interval (95% CI) are required to ensure a high positive predictive value (PPV) (11, 22, 23). Accordingly, the antigens used to design serology tests should be properly selected and cross-reactivity with antibodies directed against other antigens, including from other coronaviruses, should be verified. A huge number of serology assays have been developed and marketed in the last few months, of which 38 received FDA's EUA (as of August 31, 2020) (24, 25). Clinical performance data of commercial tests are still scant, and examples of poorly performing tests have even been reported (9). Therefore, there is an urgent need for well validated and performant serology tests, notably demonstrating very high specificity.

We describe here the analytical and clinical performance of VIDAS® SARS-CoV-2 IgM and VIDAS® SARS-CoV-2 IgG, two CE-marked and EUA-authorized automated qualitative assays for the detection of SARS-CoV-2-specific IgM and IgG, respectively, in serum or plasma. Kinetics of SARS-CoV-2-specific IgM and IgG seroconversion using the VIDAS® SARS-CoV-2 IgM and VIDAS® SARS-CoV-2 IgG assays were also compared in hospitalized and non-hospitalized COVID-19 patients.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

MATERIALS AND METHODS

Patients and samples.

SARS-CoV-2-positive samples were collected after approval by the French national review board for biomedical research in April 2020 (Comité de Protection des Personnes Sud Méditerranée I, Marseille, France) under the number ID RCB 2020-A00932-37. The international trial registration number in ClinicalTrial.gov is NCT04341142. Informed consent was obtained in accordance with the local regulations. Pre-pandemic samples (from healthy subjects and from donors with other medical conditions) were collected in accordance with the Declaration of Helsinki, as revised in 2013. Collected sera and plasma were stored frozen (< -20°C) until further testing.

Serum from up to 989 healthy pre-pandemic adult donors collected before September 2019 at two geographical sites (Etablissement Français du Sang (EFS), France; Clinilabs, Inc., United States) were used to determine the assay specificity of the VIDAS® SARS-CoV-2 IgM, IgG and combined IgM/IgG test (defined as negative if both VIDAS® SARS-CoV-2 IgM and IgG assays are negative).

For the evaluation of the positive percent agreement (PPA), 405 serum or plasma samples from 142 hospitalized and non-hospitalized symptomatic patients diagnosed with COVID-19 and confirmed positive for SARS-CoV-2 by molecular testing (cobas® SARS-CoV-2, Roche 09175431190 or Real-time RT-PCR assays for the detection of SARS-CoV-2 Institut Pasteur, Paris (26), performed at the collection site) were collected at three local hospitals (Centre Hospitalier Saint Joseph Saint Luc, Lyon, France; Centre de Ressources Biologiques [CRB] des Hospices Civils de Lyon, CRB Nord and CRB Sud, Lyon, France) between March 31 and June 2, 2020. Samples

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

were tested with the VIDAS® SARS-CoV-2 IgM and IgG assays, and paired measurements were considered for the combined IgM/IgG test results (defined as positive if at least one of the VIDAS® SARS-CoV-2 IgM and/or IgG assays is positive). The PPA was evaluated according to weekly time frames (0-7, 8-15, 16-23, 24-31, ≥ 32 days) relative to the time from RT-PCR positive result and from symptom onset, when documented.

For the evaluation of serum cross-reactivity, up to 276 frozen pre-pandemic sera (i.e. negative for SARS-CoV-2) collected from patients with other potentially interfering infections or medical conditions (bioMérieux, Centre Hospitalier Universitaire Grenoble-Alpes and St Joseph St Luc Lyon collections) were tested with the VIDAS® SARS-CoV-2 IgM (276 sera from 33 medical conditions; one to 30 sera per condition) and the VIDAS® SARS-CoV-2 IgG (261 sera from 33 medical conditions; two to 30 sera per condition) assays.

Serological assays.

VIDAS® SARS-CoV-2 IgM (423833) and VIDAS® SARS-CoV-2 IgG (423834) (bioMérieux, France) are automated qualitative CE-IVD assays developed for the VIDAS® family of instruments and based on a two-step enzyme immunoassay combined with an enzyme-linked fluorescent assay (ELFA) detection technique. The VIDAS® SARS-CoV-2 IgM and VIDAS® SARS-CoV-2 IgG assays are intended for use as an aid to determine if individuals may have been exposed and infected by SARS-CoV-2 and if they have mounted a specific anti-SARS-CoV-2 IgM and IgG immune response. These assays allow the detection of SARS-CoV-2-specific IgM and IgG, respectively, from 100 µl serum or plasma (lithium heparin). The VIDAS® SARS-CoV-2 IgM and VIDAS® SARS-

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

CoV-2 IgG serological assays were conducted according to the manufacturer's instructions. Briefly, a solid-phase receptacle coated with the antigen (recombinant SARS-CoV-2 receptor-binding domain [RBD] of the viral Spike protein) serves as both solid phase and pipetting device. After the sample dilution step, SARS-CoV-2-specific IgM and IgG are captured on the coated antigen and unbound components are washed out. In a second step, human IgM (VIDAS® SARS-CoV-2 IgM) or IgG (VIDAS® SARS-CoV-2 IgG) are specifically detected by mouse monoclonal antibodies conjugated to alkaline phosphatase and directed against human IgM or IgG, respectively. Unbound components are eliminated by washing and detection is performed by incubation with the substrate (4-Methyl-umbelliferyl phosphate) followed by measurement of the fluorescent product (4-Methyl-umbelliferone) at 450 nm. A relative fluorescence value (RFV) is generated (background reading subtracted from the final fluorescence reading). The assay is conducted with a standard (S1) and a positive control (C1) that contains humanized recombinant anti-SARS-CoV-2 antibody, either IgM or IgG depending on the assay. A negative control (C2) is also supplied. The results are automatically calculated by the instrument, according to the S1 standard, and an index value (i) is obtained (where $i=RFV_{sample}/RFV_{S1}$). The test is interpreted as negative when $i < 1.00$ and positive when $i \geq 1.00$. The positivity cut-off values for the IgM and IgG tests were determined from a healthy pre-pandemic cohort (259 [IgM test] and 120 [IgG test] samples collected prior to August 2019), using non-parametric 99th percentile because of normality rejection for the IgM positivity cut-off and using the (99,99) tolerance intervals approach after Box-Cox transformation (27) for the IgG positivity cut-off (99th percentile index values at a 99% confidence level) (data not shown).

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

Statistical analysis.

IgG positivity cut-off values were determined by the tolerance intervals approach (28) and the parametric method using the Analyse-it 5.40 and JMP 13.1.0 software. IgM positivity cut-off values were determined by the non-parametric 99th percentile using the Analyse-it 5.40 software.

Assay precision (repeatability or within-run precision, and within-laboratory precision) were evaluated according to the Clinical & Laboratory Standards Institute (CLSI) EP05-A3 guideline (29) by the variance component method and restricted maximum likelihood (REML) using the SAS Enterprise Guide 7.13 HF8 software.

Specificity and sensitivity (PPA) estimates were evaluated according to the CLSI EP12-A2 guideline (30). The 95% confidence intervals (95% CI) were computed (either as score confidence interval if the specificity or sensitivity (PPA) belonged to] 5 ; 95[%, or as exact confidence interval otherwise) using the SAS Enterprise Guide 7.13 HF8 software.

PPA was evaluated per time windows (in days) relative to the day of RT-PCR positive result and of symptom onset (when documented). Only one patient's measurement per time period was included in the analysis. In case of multiple patient's measurements in one period, the first available measurement was considered for the calculation.

The positive predictive value (PPV) and the negative predictive value (NPV) were calculated assuming a prevalence of 5%, as recommended by FDA for the EUA application (25), and the

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

respective 95% CI were computed according to Mercaldo et al. (31) using the SAS Enterprise Guide 7.13 HF8 software.

VIDAS® SARS-CoV-2 index values were displayed per time frame as Tukey box plots showing median values (horizontal line), interquartile ranges (IQR: Q3-Q1), lower and upper whiskers (Q1-1.5xIQR and Q3+1.5xIQR respectively) and outliers (below Q1-1.5xIQR and above Q3+1.5xIQR; black dots). Two-group comparisons of index values per time frame between hospitalized and non-hospitalized patients were performed using the nonparametric two-tailed Mann-Whitney *U*-test (MWU-test) with normal approximation. The Bonferroni method was applied for controlling the 5% overall probability of a false-significant result when multiple comparisons were carried out; given that three comparisons were performed, *P*-values < 0.017 (one third of 0.05) were considered statistically significant.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

RESULTS

Analytical performance of VIDAS® SARS-CoV-2 IgM and IgG assays

Within-run and within-laboratory precisions of the ELFA-based tests were determined using three samples (one negative and two positive for SARS-CoV-2 IgM and IgG). Samples were run in triplicate on one VIDAS® instrument, twice a day over 10 days (with an instrument calibration every second day), using one assay lot, thus generating 60 measurement values per sample. The coefficient of variation (%CV) for repeatability (within-run precision) did not exceed 9.3% and 5.9% for the VIDAS® SARS-CoV-2 IgM and IgG assays, respectively. The %CV for within-laboratory precision was also low, reaching a maximum of 10.7% and 6.9% for the VIDAS® SARS-CoV-2 IgM and IgG assays, respectively (Table 1).

Analytical specificity and sensitivity of the VIDAS® SARS-CoV-2 IgM and IgG assays were verified through various experiments. First, we ruled out a possible cross-reactivity of the anti-human-IgM (VIDAS® SARS-CoV-2 IgM) or of the anti-human-IgG (VIDAS® SARS-CoV-2 IgG) with human IgG or IgM, respectively, which might produce false-positive results. Spike-in experiments in negative samples using either human recombinant monoclonal anti-SARS-CoV-2 IgG (in the VIDAS® SARS-CoV-2 IgM assay) or human recombinant monoclonal anti-SARS-CoV-2 IgM (in the VIDAS® SARS-CoV-2 IgG assay) demonstrated neither reactivity of the alkaline-phosphatase-conjugated anti-human-IgM toward human IgG nor reactivity of the anti-human-IgG toward human IgM (data not shown). Second, we ruled out a possible competition between anti-SARS-CoV-2 IgM and IgG for binding to the coated SARS-CoV-2 antigen, which might interfere with the respective assays and generate false-negative results. Spike-in experiments in positive samples using increasing amounts of human recombinant monoclonal anti-SARS-CoV-2 IgG (in the

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

VIDAS® SARS-CoV-2 IgM assay) or of human recombinant monoclonal anti-SARS-CoV-2 IgM (in the VIDAS® SARS-CoV-2 IgG assay) did not impact the test results (data not shown). Third, we evaluated the impact of serum inactivation (56°C for 30 minutes), which might be applied by diagnostics laboratories to inactivate potentially infectious samples (32), on test results of negative and positive samples. Heat inactivation affected significantly VIDAS® SARS-CoV-2 IgM and IgG assay outcome (data not shown) and should therefore be avoided. Finally, we evaluated the possible cross-reactivity of components of the assay (SARS-CoV-2 antigen RBD or immunoglobulins) with human sera from patients with other infections (including other coronaviruses) or medical conditions (e.g. rheumatoid factor) (33) that might interfere with the assay and yield false-positive results. Up to 276 (VIDAS® SARS-CoV-2 IgM) and 261 (VIDAS® SARS-CoV-2 IgG) sera of SARS-CoV-2-negative patients with other infections or conditions were tested and the number of positive test results was evaluated (Table 2). None of the 18 sera of patients with an history of infection with the human coronaviruses CoV-NL63, CoV-229E, CoV-HKU1 or CoV-OC43 (genera *Alphacoronavirus* and *Betacoronavirus*) were positive in the VIDAS® SARS-CoV-2 IgG assay, while the serum of one CoV-NL63-positive patient was positive in the VIDAS® SARS-CoV-2 IgM assay. Only two out of 261 (0.8%) tested sera were positive in the VIDAS® SARS-CoV-2 IgG assay. They belonged to a HIV-positive and a respiratory syncytial virus (RSV A)-positive patient, respectively. On the other hand, ten out of 276 (3.6%) tested sera were positive in the VIDAS® SARS-CoV-2 IgM assay. Apart from the one CoV-NL63-positive sample mentioned above, six sera were from patients presenting autoantibodies (antinuclear antibody, rheumatoid factor), two were from patients with an history of parasite infection (*Plasmodium falciparum*, *Trypanosoma cruzi*), and one from a past Rhinovirus/Enterovirus infection. None of

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

the sera from patients infected with other respiratory viruses, including influenza virus, parainfluenza virus, metapneumovirus or adenovirus were reactive.

Clinical performance of VIDAS® SARS-COV-2 IgM and IgG assays

The clinical specificity of the VIDAS® SARS-CoV-2 IgM and IgG assays were assessed using sera from 989 pre-pandemic healthy volunteers collected in France and in the United States before September 2019. All 989 sera were tested with the VIDAS® SARS-CoV-2 IgG assay, while 308 samples were tested with the VIDAS® SARS-CoV-2 IgM assay. The combined IgM/IgG assay specificity (defined as both VIDAS® SARS-CoV-2 IgM and IgG assays being negative) was determined on 308 paired VIDAS® SARS-CoV-2 IgM and IgG tests (Table S1 and Table 3). 306/308 (VIDAS® SARS-CoV-2 IgM) and 988/989 (VIDAS® SARS-CoV-2 IgG) SARS-CoV-2-negative sera were negative, corresponding to a specificity (95% CI) of 99.4% (97.7-99.9%) and 99.9% (99.4-100%) for the VIDAS® SARS-CoV-2 IgM and IgG assays, respectively (Table 3). The specificity (95% CI) of the VIDAS® SARS-CoV-2 IgG test on the common cohort (N=308) was 100.0% (98.8-100.0%). The specificity (95% CI) of the combined IgM and IgG serology tests (306/308 tests negative in both assays) was 99.4% (97.7-99.9%) (Table 3).

The clinical sensitivity of the VIDAS® SARS-CoV-2 IgM and IgG assays was assessed using 405 samples collected from 142 patients confirmed positive for SARS-CoV-2 by RT-PCR. The positive percent agreement (PPA) of the serology tests with the RT-PCR test results was calculated per weekly time windows (0-7, 8-15, 16-23, 24-31 and ≥ 32 days) relative to the time from the PCR-positive result and to the time from symptom onset. No more than one patient sample per time

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

window was included in the calculation (Fig. 1 and Table S2). The PPA calculated on all available samples for the VIDAS® SARS-CoV-2 IgM and IgG assays are shown in Tables S3 and S4, respectively. For the sake of comparability, the PPA of the IgM, IgG and combined IgM/IgG test results was also calculated on paired samples (i.e. tested with both the IgM and IgG assays; Tables 4 and 5).

The PPA (95% CI) from the time of RT-PCR-positive test results raised from 44.5% (35.6-53.9%) and 45.5% (36.5-54.8%) at 0-7 days, to 81.7% (70.1-89.4%) and 88.3% (77.8-94.2%) at 8-15 days, to 81.6% (66.6-90.8%) and 94.7% (82.7-98.5%) at 16-23 days, to 100.0% (75.3-100.0%) and 100.0% (75.3-100.0%) at 24-31 days, and to 81.8% (52.3-94.9%) and 100.0% (71.5-100.0%) at ≥ 32 days for the VIDAS® SARS-CoV-2 IgM and IgG assays, respectively (Table 4). The PPA (95% CI) of the combined IgM and IgG serology tests (positive in at least one of the IgM and/or IgG assays) from the time of RT-PCR-positive test results, increased from 53.6% (44.4-62.7%) at 0-7 days, to 95.0% (86.1-99.0%) at 8-15 days, up to 100.0% at 16-23 days, 24-31 days and ≥ 32 days (with respective 95% CI of 90.7-100.0%, 75.3-100.0% and 71.5-100.0%) (Table 4). The PPA (95% CI) evaluated relative to the time of symptom onset raised from 31.8% (16.4-52.7%) and 31.8% (16.4-52.7%) at 0-7 days, to 82.8% (65.5-92.4%) and 86.2% (69.4-94.5%) at 8-15 days, to 100.0% (86.8-100.0%) and 96.2% (80.4-99.9%) at 16-23 days, to 100.0% (81.5-100.0%) and 94.4% (74.2-99.0%) at 24-31 days, and to 100.0% (69.2-100.0%) and 100.0% (69.2-100.0%) at ≥ 32 days for the VIDAS® SARS-CoV-2 IgM and IgG assays, respectively (Table 5). The PPA (95% CI) of the combined IgM and IgG serology test results from the time of symptom onset, increased from 36.4% (19.7-57.0%) at 0-7 days, to 89.7% (73.6-96.4%) at 8-15 days, up to 100.0% at 16-23 days,

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

24-31 days and ≥ 32 days (with respective 95% CI of 86.8-100.0%, 81.5-100.0% and 69.2-100.0%) (Table 5).

Based on the specificity and sensitivity (i.e. PPA) determined on paired IgM and IgG testing (N=308 for specificity; N=105 for PPA), the negative predictive value (NPV) and the positive predictive value (PPV) were calculated at 5% prevalence (25), according to the time after symptom onset (Table 6). The NPV was high for both the VIDAS® SARS-CoV-2 IgM and IgG assays, whether considered alone or in combination; NPV was ≥ 96.5% (lower 95% confidence limits ≥ 95.4%) at 0-7 days post symptom onset and NPV increased from 99.1% to 100.0% (lower 95% confidence limits ≥ 98.0%) from day 8 onwards following symptom onset. The PPV of the VIDAS® SARS-CoV-2 IgG assay was 100% at all time frames considered. Of note, the PPV calculated using the full data set for the VIDAS® SARS-CoV-2 IgG specificity determination (N=989) was slightly lower, increasing from 94.3% at 0-7 days to 98.1% at ≥ 32 days (Table S5). The PPV (95% CI) of the VIDAS® SARS-CoV-2 IgM assay was lower, ranging from 72.1% (36.3-92.1%) at 0-7 days to 89.0% (67.1-97.0%) from day 16 onwards following symptom onset (Table 6). The combination of IgM and IgG test results slightly improved the PPV and NPV of the SARS-CoV-2 IgM assay, and the NPV of the SARS-CoV-2 IgG assay. The SARS-CoV-2 IgG assay performed best alone in terms of PPV (Table 6).

Longitudinal study of IgM and IgG seroconversion in hospitalized COVID-19 patients

The global distribution of VIDAS® SARS-CoV-2 IgM and IgG index values post symptom onset was compared among the 105 SARS-CoV-2-positive patients described in Table 5 (Fig. 2). IgM index

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

values increased from the second week of symptom onset (8-15 days) and peaked during the third week (16-23 days) before decreasing. In comparison, the IgG index values strongly increased from the second week of symptom onset and seemed to reach a plateau ≥ 32 days post symptom onset (Fig. 2).

The VIDAS® SARS-CoV-2 IgM and IgG index values were also compared between hospitalized and non-hospitalized patients. Since the date of symptom onset was not documented in non-hospitalized patients (Table S2), the index values were compared relative to the time of the RT-PCR-positive results (Fig. 3). Interestingly, the distribution of index values between hospitalized and non-hospitalized patients differ statistically from each other for both the VIDAS® SARS-CoV-2 IgM and IgG assays at the three compared time frames (0-7, 8-15 and 16-23 days post PCR-positive test; MWU-test p-values < 0.017). Median index values were higher in hospitalized versus non-hospitalized patients (Fig. 3).

Finally, IgM and IgG seroconversion was further investigated in four selected hospitalized patients with either early and/or repeated measurements over an extended period of time (up to 74 days post symptom onset; Fig. 4). IgG seroconversion closely followed IgM seroconversion in the second week of symptom onset (Fig. 4A-B), in line with the global profile shown in Figure 2. SARS-CoV-2 IgM index rapidly decreased concomitantly with the increase of SARS-CoV-2 IgG index (Fig. 4B-D). In the three patients shown in Fig. 4B-D, SARS-CoV-2 IgM index decreased below the positivity cutoff (index = 1.00) 46 days after symptom onset. In contrast, SARS-CoV-2 IgG index values remained high and stable from approximately day 20 onward after symptom onset, at least up to 74 days.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

DISCUSSION

We describe here the analytical and clinical performance of the VIDAS® SARS-CoV-2 IgM and IgG assays. We demonstrate that both assays show high precision, and excellent analytical and clinical performances.

The rate of cross-reactivity with non-specific antibodies, including those of patients infected with other coronaviruses, was very low in both VIDAS® SARS-CoV-2 IgM and IgG assays. This weak cross-reactivity with other coronaviruses antibodies is likely due, at least in part, to the choice of the receptor-binding domain (RBD) of the viral Spike protein as SARS-CoV-2-specific antigen. The RBD shows a high sensitivity in ELISA, higher than that of the SARS-CoV-2 S1 or NC antigens (34–38). It also presents a weaker homology and significant structural divergences with the RBD of other coronaviruses (39–42). Another advantage of using the RBD is that the viral antigen generates neutralizing antibodies likely to provide protective immunity (41–48), as previously demonstrated for SARS-CoV-1 (49–51). Beside its strong immunogenicity and antigenicity, the RBD of SARS-CoV-1 has been shown to elicit antibody responses that persisted many years after infection (44, 51), raising the possibility that it might also be the case for the RBD of SARS-CoV-2. Recent studies in COVID-19 patients, notably in convalescent donors (52–54), on the anti-RBD antibody dynamics post SARS-CoV-2 infection (45, 46), or demonstrating the persistence and expansion of SARS-CoV-2-specific memory lymphocytes (55), as well as the stability of the IgG response detected with the VIDAS® SARS-CoV-2 IgG assay up to 74 days post-symptom onset in the present study, strongly support this proposition. Hence, a serology test such as the VIDAS® SARS-CoV-2 IgG assay is likely to be suitable for the detection of protective

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

immunity and the evaluation of the efficacy of future vaccines, which are mainly based on the RBD-containing Spike protein (56, 57).

The low cross-reactivity rate with non-specific sera probably explains the very high specificity (≥ 99%) and narrow 95% CI of both VIDAS® SARS-CoV-2 IgM and IgG assays. The VIDAS® SARS-CoV-2 IgG assay alone had a specificity close to 100%, slightly higher than that of the VIDAS® SARS-CoV-2 IgM assay.

The clinical sensitivity of the VIDAS® SARS-CoV-2 assays was evaluated in SARS-CoV-2-confirmed symptomatic cases and was determined as positive percent agreement (PPA) with the RT-PCR assay, at successive time frames post positive PCR and, alternatively, post symptom onset. The PPA reached 100% at 16-23 days (VIDAS® SARS-CoV-2 IgM) and at ≥ 32 days (VIDAS® SARS-CoV-2 IgG) post-symptom onset. The combined VIDAS® SARS-CoV-2 IgM/IgG test evaluation improved the PPA of the respective IgM and IgG tests by 3.5 to 6.9 percent points during the first two weeks (0-7 and 8-15 days) of symptom onset. Such improved sensitivity of the combined IgM/IgG tests early after symptom onset might also be useful for the diagnosis of suspected COVID-19 cases with negative PCR (13–15, 17, 19–21).

Overall, the clinical performance of the VIDAS® SARS-CoV-2 assays was excellent. It outperformed or was similar to that reported for existing EUA serological assays (25, 38, 58–66). The high specificity of the VIDAS® SARS-CoV-2 IgG assay alone should be well suited for epidemiological surveillance.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

The kinetics of SARS-CoV-2 IgM and IgG seroconversion was also evaluated by monitoring VIDAS® index values over time. VIDAS® SARS-CoV-2 IgM and IgG index values increased in the second week after symptom onset. IgG index values strongly increased and remained high, as IgM index values rapidly declined. These profiles are in agreement with those described in recent publications (13, 34, 45, 46, 67–72). Interestingly, the magnitude of the antibody response (index values) correlated with disease severity, as it was significantly higher in hospitalized vs. non-hospitalized COVID-19 patients at the time frames investigated (0-7, 18-15 and 16-23 days after a PCR-positive test). This observation is in agreement with published reports (11, 46, 72–75).

This study presents several limitations. First, assay sensitivity was evaluated on confirmed but not on suspected SARS-CoV-2 cases (i.e. patients with symptoms but negative by PCR). It would be interesting to evaluate and confirm the benefit of SARS-CoV-2 IgM and IgG serology to complement PCR testing (13, 14, 20, 21). On the other hand, recent reports suggested that the identification rate of false-negative PCR results using serology testing might be marginal, between ~1% (23) and ~4% (72). Second, assay sensitivity was determined on symptomatic (hospitalized and non-hospitalized) COVID-19 patients. The sensitivity of the VIDAS® SARS-CoV-2 IgM and IgG assays in asymptomatic SARS-CoV-2-infected individuals, who may represent most of the infected patients, remains to be evaluated.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

In conclusion, the VIDAS® SARS-CoV-2 IgM and IgG assays are highly sensitive and specific assays for reliable patient monitoring after acute SARS-CoV-2 infections (and likely after vaccination, when available). Moreover, the VIDAS® SARS-CoV-2 IgG assay fulfils the specificity requirement for its use in seroepidemiology studies and is well suited for the detection of past SARS-CoV-2 infections. Further studies are necessary to evaluate its suitability for the detection of SARS-CoV-2 neutralizing antibodies and to define correlates of immune protection.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

ACKNOWLEDGMENTS

This work was supported by bioMérieux. We thank the Etablissement Français du Sang, notably Yves Mérieux, for providing samples. We thank all the members of R&D Immunoassay bioMérieux who took part in this work, i.e. the bioMolecule Engineering team, Prototyping, Development and Verification teams. We warmly thank Nadia Piga and the biobank team for collecting the samples in a short time frame. We are grateful to the bioMérieux Data Sciences team for the calculations and statistical evaluation of the data, and to Victor Bondanese, Laurence Bridon and the Clinical Affairs team of bioMérieux for their help and technical support. We thank Karen Brengel for her useful advices as well as Alice Banz for critically reading the manuscript. The authors thank Dr. Anne Rascle of AR Medical Writing (Regensburg, Germany) for providing medical writing support, which was funded by bioMérieux (Marcy L'Etoile, France) in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

Conflict of interests' statement

JL declares received research funding from bioMérieux for this study.

MP declares a consulting contract with bioMérieux.

NR, SD, ND, FR, SP, CT, CP, GG, PB, MC, IC, ML and FB are employees from bioMérieux, an *in vitro* diagnostic company.

Contributions

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

NR, SD, ML, CT, FB conceived the study; CP, GG, PB, MC conceived the study and performed the serological assays. FR, SP, MP, JL collected patients' samples; NC, IC, NR, CT, ML, interpreted the serological assays; all authors contributed to data acquisition, data analysis, and/or data interpretation, and all authors reviewed and approved the final manuscript.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

REFERENCES

1. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, Chen H-D, Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X, Zheng X-S, Zhao K, Chen Q-J, Deng F, Liu L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao G-F, Shi Z-L. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273.

2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. 2020. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5:536–544.

3. World Health Organization. 2020. Coronavirus Disease (COVID-19) Situation Reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed: September 25, 2020.

4. Dong E, Du H, Gardner L. 2020. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 20:533–534.

5. Johns Hopkins University. 2020. COVID-19 Resource Center. https://coronavirus.jhu.edu/map.html. Accessed: September25, 2020.

6. World Health Organization. 2020. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. https://www.who.int/publications-detail-redirect/10665-331501. Accessed: September 25, 2020.

7. World Health Organization. 2020. Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance. https://www.who.int/publications-detail-redirect/global-

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

surveillance-for-covid-19-caused-by-human-infection-with-covid-19-virus-interim-guidance. Accessed: August 20, 2020.

8. World Health Organization. 2020. Laboratory testing strategy recommendations for COVID-19: interim guidance. https://www.who.int/publications-detail-redirect/laboratory-testing-strategy-recommendations-for-covid-19-interim-guidance. Accessed: August 20, 2020.

9. Vashist SK. 2020. In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends. Diagnostics 10:202.

10. Venter M, Richter K. 2020. Towards effective diagnostic assays for COVID-19: a review. J Clin Pathol jclinpath-2020-206685.

11. Bohn MK, Lippi G, Horvath A, Sethi S, Koch D, Ferrari M, Wang C-B, Mancini N, Steele S, Adeli K. 2020. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence. Clinical Chemistry and Laboratory Medicine (CCLM) 58:1037–1052.

12. Winter AK, Hegde ST. 2020. The important role of serology for COVID-19 control. The Lancet Infectious Diseases S1473309920303224.

13. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L, Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L, Wang J. 2020. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis https://doi.org/10.1093/cid/ciaa310.

14. Zhao R, Li M, Song H, Chen J, Ren W, Feng Y, Gao GF, Song J, Peng Y, Su B, Guo X, Wang Y, Chen J, Li J, Sun H, Bai Z, Cao W, Zhu J, Zhang Q, Sun Y, Sun S, Mao X, Su J, Chen X, He A, Gao W, Jin R, Jiang Y,

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

Sun L. 2020. Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection. Clinical Infectious Diseases ciaa523.

15. Caruana G, Croxatto A, Coste AT, Opota O, Lamoth F, Jaton K, Greub G. 2020. Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results. Clinical Microbiology and Infection 26:1178–1182.

16. Clapham H, Hay J, Routledge I, Takahashi S, Choisy M, Cummings D, Grenfell B, Metcalf CJE, Mina M, Barraquer IR, Salje H, Tam CC. 2020. Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity. Emerg Infect Dis 26:1978–1986.

17. Espejo AP, Akgun Y, Al Mana AF, Tjendra Y, Millan NC, Gomez-Fernandez C, Cray C. 2020. Review of Current Advances in Serologic Testing for COVID-19. American Journal of Clinical Pathology 154:293–304.

18. Pancrazzi A, Magliocca P, Lorubbio M, Vaggelli G, Galano A, Mafucci M, Duranti D, Cortesi M, Mazzeschi E, Fabbroni S, Viti G, Tartaglia Polcini A, Tripodo E, Sanchini P, Gervino S, Tacconi D, Dei S, Mazzierli M, D'Urso A, Ognibene A. 2020. Comparison of serologic and molecular SARS-CoV 2 results in a large cohort in Southern Tuscany demonstrates a role for serologic testing to increase diagnostic sensitivity. Clinical Biochemistry S0009912020307918.

19. Wang P. 2020. Combination of serological total antibody and RT-PCR test for detection of SARS-COV-2 infections. Journal of Virological Methods 283:113919.

20. Zhang J, Zhang X, Liu J, Ban Y, Li N, Wu Y, Liu Y, Ye R, Liu J, Li X, Li L, Qin X, Zheng R. 2020. Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing. Int Immunopharmacol 88:106861.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

21. Liu R, Liu X, Yuan L, Han H, Shereen MA, Zhen J, Niu Z, Li D, Liu F, Wu K, Luo Z, Zhu C. 2020. Analysis of adjunctive serological detection to nucleic acid test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis. Int Immunopharmacol 86:106746.

22. Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Boum Yap, Hayford K, Luquero FJ, Mina MJ, Rodriguez-Barraquer I, Wu JT, Wade D, Vernet G, Leung DT. 2020. Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward. Sci Immunol 5:eabc6347.

23. Farnsworth CW, Anderson NW. 2020. SARS-CoV-2 Serology: Much Hype, Little Data. Clinical Chemistry hvaa107.

24. U.S. Food and Drug Administration. 2020. In Vitro Diagnostics EUAs. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas. Accessed: August 20, 2020.

25. U.S. Food and Drug Administration. 2020. EUA Authorized Serology Test Performance. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance. Accessed: August 31, 2020.

26. World Health Organization. Real-time RT-PCR assays for the detection of SARS-CoV-2 Institut Pasteur, Paris. https://www.who.int/nepal/activities/supporting-elimination-of-kala-azar-as-a-public-health-problem/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris. Accessed: August 20, 2020.

27. Dong X, Tsong Y, Shen M. 2015. Statistical considerations in setting product specifications. J Biopharm Stat 25:280–294.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

28. Dong X, Tsong Y, Shen M, Zhong J. 2015. Using Tolerance Intervals for Assessment of Pharmaceutical Quality. Journal of Biopharmaceutical Statistics 25:317–327.

29. Clinical & Laboratory Standards Institute. EP05-A3: Evaluating Quantitative Measurement Precision, 3rd Edition. https://clsi.org/standards/products/method-evaluation/documents/ep05/. Accessed: August 20, 2020.

30. Clinical & Laboratory Standards Institute. EP12-A2: User Protocol for Evaluation of Qualitative Test Performance, 2nd Edition. https://clsi.org/standards/products/method-evaluation/documents/ep12/. Accessed: August 20, 2020.

31. Mercaldo ND, Lau KF, Zhou XH. 2007. Confidence intervals for predictive values with an emphasis to case-control studies. Stat Med 26:2170–2183.

32. Pastorino B, Touret F, Gilles M, de Lamballerie X, Charrel RN. 2020. Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics? Viruses 12:735.

33. Tate J, Ward G. 2004. Interferences in immunoassay. Clin Biochem Rev 25:105–120.

34. Ma H, Zeng W, He H, Zhao D, Yang Y, Jiang D, Zhou P, Qi Y, He W, Zhao C, Yi R, Wang X, Wang B, Xu Y, Yang Y, Kombe AJK, Ding C, Xie J, Gao Y, Cheng L, Li Y, Ma X, Jin T. 2020. COVID-19 diagnosis and study of serum SARS-CoV-2 specific IgA, IgM and IgG by chemiluminescence immunoanalysis. medRxiv 2020.04.17.20064907.

35. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers MM, Sikkema RS, de Bruin E, Chandler FD, Yazdanpanah Y, Le Hingrat Q, Descamps D, Houhou-Fidouh N, Reusken CBEM, Bosch B-J, Drosten C, Koopmans MPG, Haagmans BL. 2020. Severe Acute Respiratory Syndrome

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

Coronavirus 2–Specific Antibody Responses in Coronavirus Disease 2019 Patients. Emerg Infect Dis 26.

36. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, Yip CC-Y, Cai J-P, Chan JM-C, Chik TS-H, Lau DP-L, Choi CY-C, Chen L-L, Chan W-M, Chan K-H, Ip JD, Ng AC-K, Poon RW-S, Luo C-T, Cheng VC-C, Chan JF-W, Hung IF-N, Chen Z, Chen H, Yuen K-Y. 2020. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 20:565–574.

37. Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, Wang Q, Tan L, Wu W, Tang S, Xiong Z, Zheng S. 2020. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2. Journal of Clinical Microbiology 58.

38. Lassaunière R, Frische A, Harboe ZB, Nielsen AC, Fomsgaard A, Krogfelt KA, Jørgensen CS. 2020. Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv 2020.04.09.20056325.

39. Chen Y, Guo Y, Pan Y, Zhao ZJ. 2020. Structure analysis of the receptor binding of 2019-nCoV. Biochemical and Biophysical Research Communications 525:135–140.

40. Jaimes JA, André NM, Chappie JS, Millet JK, Whittaker GR. 2020. Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop. J Mol Biol 432:3309–3325.

41. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J, Lan J, Yuan J, Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu L, Zhao J, Wang X, Zhang Z, Zhang L. 2020. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature https://doi.org/10.1038/s41586-020-2380-z.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

42. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, Cornaby C, Bartelt L, Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Rouphael N, Edupuganti S, Weiskopf D, Tse LV, Hou YJ, Margolis D, Sette A, Collins MH, Schmitz J, Baric RS, de Silva AM. 2020. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol 5:eabc8413.

43. Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, Gao G, Hu X, Zhang Y, Tong Z, Huang W, Liu WJ, Wu G, Zhang B, Wang L, Qi J, Feng H, Wang F, Wang Q, Gao GF, Yuan Z, Yan J. 2020. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature https://doi.org/10.1038/s41586-020-2381-y.

44. Chia WN, Tan CW, Foo R, Kang AEZ, Peng Y, Sivalingam V, Tiu C, Ong XM, Zhu F, Young BE, Chen MI-C, Tan Y-J, Lye DC, Anderson DE, Wang L-F. 2020. Serological differentiation between COVID-19 and SARS infections. Emerging Microbes & Infections 9:1497–1505.

45. Grandjean L, Saso A, Ortiz A, Lam T, Hatcher J, Thistlethwaite R, Harris M, Best T, Johnson M, Wagstaffe H, Ralph E, Mai A, Colijn C, Breuer J, Buckland M, Gilmour K, Goldblatt D, Team TC-SS. 2020. Humoral Response Dynamics Following Infection with SARS-CoV-2. medRxiv 2020.07.16.20155663.

46. Crawford KH, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, Shuey K, Casto AM, Fiala B, Wrenn S, Pettie D, King NP, Chu HY, Bloom JD. 2020. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. medRxiv 2020.08.06.20169367.

47. McAndrews KM, Dowlatshahi DP, Dai J, Becker LM, Hensel J, Snowden LM, Leveille JM, Brunner MR, Holden K, Hopkins NS, Harris A, Kumpati JJ, Whitt MA, Lee JJ, Ostrosky-Zeichner L, Papanna R, LeBleu V, Allison J, Kalluri R. 2020. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

domain and nucleocapsid with implications on COVID-19 immunity. JCI Insight https://doi.org/10.1172/jci.insight.142386.

48. Wan J, Xing S, Ding L, Wang Y, Gu C, Wu Y, Rong B, Li C, Wang S, Chen K, He C, Zhu D, Yuan S, Qiu C, Zhao C, Nie L, Gao Z, Jiao J, Zhang X, Wang X, Ying T, Wang H, Xie Y, Lu Y, Xu J, Lan F. 2020. Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection. Cell Reports 32:107918.

49. He Y, Zhu Q, Liu S, Zhou Y, Yang B, Li J, Jiang S. 2005. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 334:74–82.

50. Pak JE, Sharon C, Satkunarajah M, Auperin TC, Cameron CM, Kelvin DJ, Seetharaman J, Cochrane A, Plummer FA, Berry JD, Rini JM. 2009. Structural Insights into Immune Recognition of the Severe Acute Respiratory Syndrome Coronavirus S Protein Receptor Binding Domain. Journal of Molecular Biology 388:815–823.

51. Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T, He Y. 2010. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol J 7:299.

52. Li L, Tong X, Chen H, He R, Lv Q, Yang R, Zhao L, Wang J, Xu H, Liu C, Chen G, Chen S, Li C, Qiao J, Yang J, Wu Y, Liu Z. 2020. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Transfusion https://doi.org/10.1111/trf.15918.

53. Salazar E, Kuchipudi SV, Christensen PA, Eagar TN, Yi X, Zhao P, Jin Z, Long SW, Olsen RJ, Chen J, Castillo B, Leveque C, Towers DM, Lavinder J, Gollihar JD, Cardona J, Ippolito GC, Nissly RH, Bird IM, Greenawalt D, Rossi RM, Gontu A, Srinivasan S, Poojary IB, Cattadori IM, Hudson PJ, Joselyn N, Prugar L, Huie K, Herbert A, Bernard DW, Dye J, Kapur V, Musser JM. 2020. Relationship between

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma. bioRxiv https://doi.org/10.1101/2020.06.08.138990.

54. Yao X-Y, Liu W, Li Z-Y, Xiong H-L, Su Y-Y, Li T, Zhang S-Y, Zhang X-J, Bi Z-F, Deng C-X, Li C-Y, Yuan Q, Zhang J, Zhang T-Y, Wang Z-X, Ge S, Ningshao X. 2020. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. medRxiv 2020.07.18.20156810.

55. Pepper M, Rodda L, Netland J, Shehata L, Pruner K, Morawski P, Thouvenel C, Takahara K, Eggenberger J, Hemann E, Waterman H, Fahning M, Chen Y, Rathe J, Stokes C, Wrenn S, Fiala B, Carter L, Hamerman J, King N, Gale M, Campbell D, Rawlings D. 2020. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Res Sq https://doi.org/10.21203/rs.3.rs-57112/v1.

56. Dagotto G, Yu J, Barouch DH. 2020. Approaches and Challenges in SARS-CoV-2 Vaccine Development. Cell Host Microbe https://doi.org/10.1016/j.chom.2020.08.002.

57. Amanat F, Krammer F. 2020. SARS-CoV-2 Vaccines: Status Report. Immunity 52:583–589.

58. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, Jerome KR, Mathias PC, Greninger AL. 2020. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. J Clin Microbiol https://doi.org/10.1128/JCM.00941-20.

59. Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, Farnsworth CW. 2020. Clinical Performance of Two SARS-CoV-2 Serologic Assays. Clinical Chemistry hvaa120.

60. Tuaillon E, Bolloré K, Pisoni A, Debiesse S, Renault C, Marie S, Groc S, Niels C, Pansu N, Dupuy AM, Morquin D, Foulongne V, Bourdin A, Le Moing V, Van de Perre P. 2020. Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients. J Infect 81:e39–e45.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

61. Perkmann T, Perkmann-Nagele N, Breyer M-K, Breyer-Kohansal R, Burghuber OC, Hartl S, Aletaha D, Sieghart D, Quehenberger P, Marculescu R, Mucher P, Strassl R, Wagner OF, Binder CJ, Haslacher H. 2020. Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity. Clin Chem https://doi.org/10.1093/clinchem/hvaa198.

62. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. 2020. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. J Clin Virol 129:104480.

63. Caini S, Bellerba F, Corso F, Díaz-Basabe A, Natoli G, Paget J, Facciotti F, De Angelis SP, Raimondi S, Palli D, Mazzarella L, Pelicci PG, Vineis P, Gandini S. 2020. Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications. Eurosurveillance 25.

64. Chew KL, Tan SS, Saw S, Pajarillaga A, Zaine S, Khoo C, Wang W, Tambyah P, Jureen R, Sethi SK. 2020. Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection. Clinical Microbiology and Infection 26:1256.e9-1256.e11.

65. Herroelen PH, Martens GA, De Smet D, Swaerts K, Decavele A-S. 2020. Humoral Immune Response to SARS-CoV-2: Comparative Clinical Performance of Seven Commercial Serology Tests. American Journal of Clinical Pathology aqaa140.

66. Pflüger LS, Bannasch JH, Brehm TT, Pfefferle S, Hoffmann A, Nörz D, van der Meirschen M, Kluge S, Haddad M, Pischke S, Hiller J, Addo MM, Lohse AW, Wiesch JS zur, Peine S, Aepfelbacher M, Lütgehetmann M. 2020. Clinical evaluation of five different automated SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients. Journal of Clinical Virology 130:104549.

67. Xiao AT, Gao C, Zhang S. 2020. Profile of specific antibodies to SARS-CoV-2: The first report. J Infect https://doi.org/10.1016/j.jinf.2020.03.012.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

68. Zhou Q, Zhu D, Yan H, Quan J, Kuang Z, Zhang W, Huang L, Lei T, Liu J, Xiao B, Luo A, Sun Z, Li L. 2020. A preliminary study on analytical performance of serological assay for SARS-CoV-2 IgM/IgG and application in clinical practice. medRxiv 2020.05.05.20092551.

69. Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M. 2020. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clinical Chemistry and Laboratory Medicine (CCLM) 1.

70. Suhandynata RT, Hoffman MA, Kelner MJ, McLawhon RW, Reed SL, Fitzgerald RL. 2020. Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19. The Journal of Applied Laboratory Medicine jfaa079.

71. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, Peng P, Liu X, Chen Z, Huang H, Zhang F, Luo W, Niu X, Hu P, Wang L, Peng H, Huang Z, Feng L, Li F, Zhang F, Li F, Zhong N, Chen L. 2020. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect 9:940–948.

72. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, Liao P, Qiu J-F, Lin Y, Cai X-F, Wang D-Q, Hu Y, Ren J-H, Tang N, Xu Y-Y, Yu L-H, Mo Z, Gong F, Zhang X-L, Tian W-G, Hu L, Zhang X-X, Xiang J-L, Du H-X, Liu H-W, Lang C-H, Luo X-H, Wu S-B, Cui X-P, Zhou Z, Zhu M-M, Wang J, Xue C-J, Li X-F, Wang L, Li Z-J, Wang K, Niu C-C, Yang Q-J, Tang X-J, Zhang Y, Liu X-M, Li J-J, Zhang D-C, Zhang F, Liu P, Yuan J, Li Q, Hu J-L, Chen J, Huang A-L. 2020. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 26:845–848.

73. Yongchen Z, Shen H, Wang X, Shi X, Li Y, Yan J, Chen Y, Gu B. 2020. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. Emerging Microbes & Infections 9:833–836.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

74. Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J, Chu Y, Feng Y, Wang Q. 2020. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients. Clin Infect Dis https://doi.org/10.1093/cid/ciaa721.

75. Hansen CB, Jarlhelt I, Pérez-Alós L, Hummelshøj Landsy L, Loftager M, Rosbjerg A, Helgstrand C, Bjelke JR, Egebjerg T, Jardine JG, Sværke Jørgensen C, Iversen K, Bayarri-Olmos R, Garred P, Skjoedt M-O. 2020. SARS-CoV-2 antibody responses determine disease severity in COVID-19 infected individuals. medRxiv 2020.07.27.20162321.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

TABLES

Table 1. Precision of the VIDAS® SARS-CoV-2 IgM and IgG assays

VIDAS® SARS-CoV-2 assay	Sample	Total number of measurements	Mean index	Repeatability (within-run precision)		Within-laboratory precision	
				SD	CV (%)	SD	CV (%)
IgM	A (negative, high)	60	0.95	0.08	8.5	0.09	9.4
	B (positive)	60	1.50	0.14	9.3	0.16	10.7
	C (positive)	60	5.78	0.42	7.3	0.46	8.0
IgG	D (negative, high)	60	0.88	0.03	3.8	0.04	4.5
	E (positive)	60	1.42	0.08	5.5	0.09	6.5
	F (positive)	60	8.04	0.48	5.9	0.55	6.9

Abbreviations: SD, standard deviation; CV, coefficient of variation

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

Table 2. Cross-reactivity of human sera from patients with other infections or medical conditions potentially interfering with the VIDAS® SARS-CoV-2 IgM and IgG assays

Sample category	VIDAS® SARS-CoV-2 IgM		VIDAS® SARS-CoV-2 IgG	
	No. samples tested	No. positive tests	No. samples tested	No. positive tests
Pregnant women	5	0	5	0
Antinuclear antibody (ANA)[a]	47	2	47	0
Rheumatoid factor	19	4	19	0
Human anti-mouse antibody (HAMA)	5	0	5	0
Borrelia burgdorferi	10	0	6	0
Haemophilus Influenzae B	5	0	5	0
Plasmodium falciparum	3	1	3	0
Toxoplasma gondii	10	0	6	0
Treponema pallidum	3	0	3	0
Trypanosoma cruzi	5	1	5	0
Hepatitis A virus (HAV)	3	0	3	0
Hepatitis B virus (HBV)	5	0	5	0
Hepatitis C virus (HCV)	5	0	5	0
Hepatitis E virus (HEV)	7	0	6	0
Herpes simplex virus (HSV)	6	0	6	0
Human immunodeficiency virus (HIV)	5	0	5	1
Cytomegalovirus (CMV)	4	0	3	0
Measles virus (MV)	4	0	3	0
Mumps virus (MuV)	1	0	3	0
Rubella virus (RuV)	10	0	6	0
Dengue virus (DENV)	3	0	3	0
West Nile virus (WNV)	4	0	3	0
Yellow fever virus (YFV)	4	0	3	0
Zika virus (ZIKV)	5	0	5	0
Adenovirus (AdV)	2	0	2	0
Metapneumovirus (MPV)	4	0	4	0
Rhinovirus/Enterovirus (RV/EnteroV)[b]	20	1	20	0
Influenza A and B virus (IAV/IBV)	30	0	30	0
Parainfluenza viruses 1/2/3 (PIV-1/2/3)	11	0	11	0
Respiratory syncytial virus A or B (RSV A or B)	13	0	13	1
Coronavirus NL63/HKU1 (CoV-*NL63/HKU1*)[c]	9	1	9	0
Coronavirus 229E (CoV-229E)	7	0	7	0
Coronavirus OC43 (CoV-OC43)	2	0	2	0
Total	**276**	**10**	**261**	**2**

[a]Include anti-DNA, anti-SSA, anti-SSB and anti-Sm/RNP antibodies; [b]One out of 20 sera was from a patient with a bocavirus (BoV) co-infection and was negative in both VIDAS® SARS-CoV-2 IgM and IgG assays; [c]Six out of the nine sera tested were from patients positive for CoV-NL63 and three were from patients positive for CoV-NL63 and/or CoV-HKU1.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

652 **Table 3. Specificity of the VIDAS® SARS-CoV-2 IgM and IgG assays**

VIDAS® SARS-CoV-2 serology testing	No. samples	No. negative results	Specificity	95% confidence interval (95% CI)
IgM	308	306	99.4%	97.7-99.9%
IgG[a]	989	988	99.9%	99.4-100.0%
Combined IgM/IgG[b]	308	306	99.4%	97.7-99.9%

653 [a]Specificity (95% CI) determined based on common samples (N=308) was 100.0% (98.8-100.0%); [b]combined test is negative when both
654 IgM and IgG tests are negative

655

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

Table 4. Positive percent agreement (PPA) of the VIDAS® SARS-CoV-2 IgM, IgG and combined IgM/IgG test results of paired SARS-CoV-2-positive samples, according to the time from RT-PCR-positive result

VIDAS® SARS-CoV-2 serology testing	Time from RT-PCR-positive result	Median (range) time in days	No. samples[a]	No. positive results	PPA	95% CI
IgM (N=232)	0-7 days	2 (0-7)	110	49	44.5%	35.6-53.9%
	8-15 days	14 (8-15)	60	49	81.7%	70.1-89.4%
	16-23 days	20 (16-23)	38	31	81.6%	66.6-90.8%
	24-31 days	26 (24-28)	13	13	100.0%	75.3-100.0%
	≥ 32 days	33 (32-65)	11	9	81.8%	52.3-94.9%
IgG (N=232)	0-7 days	2 (0-7)	110	50	45.5%	36.5-54.8%
	8-15 days	14 (8-15)	60	53	88.3%	77.8-94.2%
	16-23 days	20 (16-23)	38	36	94.7%	82.7-98.5%
	24-31 days	26 (24-28)	13	13	100.0%	75.3-100.0%
	≥ 32 days	33 (32-65)	11	11	100.0%	71.5-100.0%
Combined IgM/IgG[b] (N=232)	0-7 days	2 (0-7)	110	59	53.6%	44.4-62.7%
	8-15 days	14 (8-15)	60	57	95.0%	86.1-99.0%
	16-23 days	20 (16-23)	38	38	100.0%	90.7-100.0%
	24-31 days	26 (24-28)	13	13	100.0%	75.3-100.0%
	≥ 32 days	33 (32-65)	11	11	100.0%	71.5-100.0%

[a]no more than one test result per patient per time period; [b]combined test is positive when at least one of IgM and/or IgG tests are positive

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

Table 5. Positive percent agreement (PPA) of the VIDAS® SARS-CoV-2 IgM, IgG and combined IgM/IgG test results of paired SARS-CoV-2-positive samples, according to the time from symptom onset

VIDAS® SARS-CoV-2 serology testing	Time from symptom onset	Median (range) time in days	No. samples[a]	No. positive results	PPA	95% CI
IgM (N=105)	0-7 days	5.5 (1-7)	22	7	31.8%	16.4-52.7%
	8-15 days	12 (8-15)	29	24	82.8%	65.5-92.4%
	16-23 days	18 (16-23)	26	26	100.0%	86.8-100.0%
	24-31 days	26 (24-30)	18	18	100.0%	81.5-100.0%
	≥ 32 days	35 (32-65)	10	10	100.0%	69.2-100.0%
IgG (N=105)	0-7 days	5.5 (1-7)	22	7	31.8%	16.4-52.7%
	8-15 days	12 (8-15)	29	25	86.2%	69.4-94.5%
	16-23 days	18 (16-23)	26	25	96.2%	80.4-99.9%
	24-31 days	26 (24-30)	18	17	94.4%	74.2-99.0%
	≥ 32 days	35 (32-65)	10	10	100.0%	69.2-100.0%
Combined IgM/IgG[b] (N=105)	0-7 days	5.5 (1-7)	22	8	36.4%	19.7-57.0%
	8-15 days	12 (8-15)	29	26	89.7%	73.6-96.4%
	16-23 days	18 (16-23)	26	26	100.0%	86.8-100.0%
	24-31 days	26 (24-30)	18	18	100.0%	81.5-100.0%
	≥ 32 days	35 (32-65)	10	10	100.0%	69.2-100.0%

[a]no more than one test result per patient per time period; [b]combined test is positive when at least one of IgM and/or IgG tests are positive

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

Table 6. Positive and negative predictive values (PPV/NPV) at 5% prevalence of the VIDAS® SARS-CoV-2 IgM, IgG and combined IgM/IgG test results, according to the time from symptom onset

2 IgM, IgG and combined IgM/IgG test results, according to the time from symptom onset

VIDAS® SARS-CoV-2 serology testing	Time from symptom onset	PPV[a] (95% CI)	NPV[a] (95% CI)
IgM	0-7 days	72.1% (36.3-92.1%)	96.5% (95.4-97.4%)
	8-15 days	87.0% (62.5-96.4%)	99.1% (98.0-99.6%)
	16-23 days	89.0% (67.1-97.0%)	100.0% (N/A)[b]
	24-31 days	89.0% (67.1-97.0%)	100.0% (N/A)[b]
	≥ 32 days	89.0% (67.1-97.0%)	100.0% (N/A)[b]
IgG	0-7 days	100.0% (N/A)[b]	96.5% (95.4-97.4%)
	8-15 days	100.0% (N/A)[b]	99.3% (98.2-99.7%)
	16-23 days	100.0% (N/A)[b]	99.8% (98.6-100.0%)
	24-31 days	100.0% (N/A)[b]	99.7% (98.1-100.0%)
	≥ 32 days	100.0% (N/A)[b]	100.0% (N/A)[b]
Combined IgM/IgG	0-7 days	74.7% (40-92.9%)	96.7% (95.6-97.6%)
	8-15 days	87.9% (64.5-96.7%)	99.5% (98.4-99.8%)
	16-23 days	89.0% (67.1-97.0%)	100.0% (N/A)[b]
	24-31 days	89.0% (67.1-97.0%)	100.0% (N/A)[b]
	≥ 32 days	89.0% (67.1-97.0%)	100.0% (N/A)[b]

[a]PPV and NPV were calculated at 5% prevalence and using values of specificity and sensitivity (PPA) determined on paired VIDAS® SARS-CoV-2 IgM and IgG test results (N=308 for specificity, Table 3; N=105 for PPA, Table 5); [b]95% CI not calculable (division by zero)



medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

Figure 1. Study flow diagram. Description of SARS-CoV-2-positive samples used to determine the positive percent agreement relative to the time of RT-PCR-positive test result and to the time of symptom onset. The number of and reason for sample exclusion are indicated in the white boxes. Included samples are indicated in greyed boxes. Altogether, out of the 405 collected samples (from 142 SARS-CoV-2-positive patients), 232 paired samples (i.e. tested with both VIDAS® SARS-CoV-2 IgM and IgG assays) from 130 patients with a documented date for the SARS-CoV-2-specific PCR-positive test, and 105 paired samples from 63 patients with a documented date of symptom onset were available.



N	22	29	26	18	10
Median (IQR)	0.2 (0.1-1.9)	4.6 (1.9-13)	8.2 (5.9-14)	4.0 (2.7-10)	4.8 (2.0-7.2)

N	22	29	26	18	10
Median (IQR)	0.2 (0.0-1.4)	7.7 (2.1-21)	24.8 (15-33)	28.1 (19-36)	33.2 (28-37)

Figure 2. Distribution of IgM (A) and IgG (B) index values obtained using the VIDAS® SARS-CoV-2 IgM and IgG assays, respectively, in patients confirmed positive for SARS-CoV-2, according to the time from symptom onset. VIDAS® SARS-CoV-2 IgM and IgG index values of 105 paired samples from 63 SARS-CoV-2-positive patients (Table 5, Table S1 and Fig. 1) are displayed as Tukey box plots according to the time from symptom onset. No more than one patient's sample is included per time frame. The number of tested samples (N), and the median and interquartile range (IQR) of index values are indicated below each graph. The dashed line shows the positivity cut-off of both assays (i = 1.00).

medRxiv preprint doi: https://doi.org/10.1101/2020.09.29.20198080; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license.



Figure 3. Distribution of IgM (A) and IgG (B) index values obtained using the VIDAS® SARS-CoV-2 IgM and IgG assays, respectively, in hospitalized vs. non-hospitalized patients confirmed positive for SARS-CoV-2, according to the time from PCR-positive result. Out of the 232 paired samples (Tables 4 and S2), 15 samples from patients with an unknown hospitalization status were excluded from the analysis. VIDAS® SARS-CoV-2 IgM and IgG index values of 217 paired samples from 115 SARS-CoV-2-positive patients (100 samples from 54 hospitalized patients and 117 samples from 61 non-hospitalized patients) are depicted as Tukey box plots according to the time from RT-PCR-positive test result. No more than one patient's sample is included per time frame. The number of tested samples (N) and the median index are indicated below each graph. The dashed line shows the positivity cut-off of both assays (i = 1.00). Differences between the groups of hospitalized and non-hospitalized patients were tested at each time frame (0-7, 8-15, 16-23 days post positive PCR) using a two-sided MWU-test; the respective p-values are displayed above each graph. No statistical testing was performed at 24-31 and ≥ 32 days due to the too low of lack of index values in the group of non-hospitalized patients at these time points.

medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-4.0 International license.



medRxiv preprint doi: https://doi.org/10.1101/2020.09.28.20196030; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

Figure 4. Kinetics of IgM and IgG seroconversion in four selected hospitalized patients. VIDAS® SARS-CoV-2 IgM and IgG index values of four patients (A to D, respectively) measured over time after symptom onset are presented. The dashed line indicates the positivity cut-off of both assays (i = 1.00). Further patients' information is as follows: (**A**) the 78-year-old male patient was in the intensive-care unit (ICU) at all investigated time points, except at the first (day 7) and last (day 33) measurement time points; (**B**) the 77-year-old male patient was in ICU at all investigated time points; (**C**) the 43-year-old male patient was ICU at all investigated times, except at the last two measurement time points (day 71 and 74); (**D**) the 67-year-old male patient was in ICU at all investigated time points.